RT Journal Article
SR Electronic
T1 Enrollment of Participants From Marginalized Racial and Ethnic Groups
JF Neurology: Clinical Practice
FD Lippincott Williams & Wilkins
SP e200113
DO 10.1212/CPJ.0000000000200113
VO 13
IS 1
A1 Daniel G. Di Luca
A1 Eric A. Macklin
A1 Karen Hodgeman
A1 Gisel Lopez
A1 Lindsay Pothier
A1 Katherine F. Callahan
A1 Jill Lowell
A1 James Chan
A1 Aleksandar Videnovic
A1 Codrin Lungu
A1 Anthony E. Lang
A1 Irene Litvan
A1 Michael A. Schwarzschild
A1 Tatyana Simuni
YR 2023
UL http://cp.neurology.org/content/13/1/e200113.abstract
AB Background and Objectives Representation of persons from marginalized racial and ethnic groups in Parkinson disease (PD) trials has been low, limiting the generalizability of therapeutic options for individuals with PD. Two large phase 3 randomized clinical trials sponsored by the National Institute of Neurological Disorders and Stroke (NINDS), STEADY-PD III and SURE-PD3, screened participants from overlapping Parkinson Study Group clinical sites under similar eligibility criteria but differed in participation by underrepresented minorities. The goal of this research is to compare recruitment strategies of PD participants belonging to marginalized racial and ethnic groups.Methods A total of 998 participants with identified race and ethnicity consented to STEADY-PD III and SURE-PD3 from 86 clinical sites. Demographics, clinical trial characteristics, and recruitment strategies were compared. NINDS imposed a minority recruitment mandate on STEADY-PD III but not SURE-PD3.Results Ten percent of participants who consented to STEADY-PD III self-identified as belonging to marginalized racial and ethnic groups compared to 6.5% in SURE-PD3 (difference = 3.9%, 95% confidence interval [CI] 0.4%–7.5%, p value = 0.034). This difference persisted after screening (10.1% of patients in STEADY-PD III vs 5.4% in SURE-PD 3, difference = 4.7%, 95% CI 0.6%–8.8%, p value = 0.038).Discussion Although both trials targeted similar participants, STEADY-PD III was able to consent and recruit a higher percentage of patients from racial and ethnic marginalized groups. Possible reasons include differential incentives for achieving minority recruitment goals.Trial Registration Information This study used data from The Safety, Tolerability, and Efficacy Assessment of Isradipine for Parkinson Disease (STEADY-PD III; NCT02168842) and the Study of Urate Elevation in Parkinson’s Disease (SURE-PD3; NCT02642393).